Phase II trial of oral uracil/tegafur plus leucovorin in patients with hormone-refractory prostate carcinoma

Cancer

Volumn 106, Issue 8, 2006, Pages 1715-1721

  Bhandari, Manish S ^a   Pienta, Kenneth J ^a,b   Fardig, Judith ^a   Olson, Karin ^a   Smith, David C ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Chemotherapy; Fluoropyrimidines; Hormone refractory; Prostate carcinoma

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; FLUOROURACIL; FOLINIC ACID; GONADORELIN AGONIST; INTERFERON; PROSTATE SPECIFIC ANTIGEN; TEGAFUR; UFT;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; MALE; METASTASIS; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; THROMBOCYTOPENIA; VOMITING;

ADENOCARCINOMA; ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TEGAFUR; URACIL;

EID: 33646075481     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21815     Document Type: Article

References (38)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin. 1999;49:8-31.
2. Lepor H, Ross A, Walsh PC. The influence of hormonal therapy on survival of men with advanced prostatic cancer. J Urol. 1982;128:335-340.
3. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-1520.
4. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512.
5. Scott WW, Johnson DE, Schmidt JE, et al. Chemotherapy of advanced prostatic carcinoma with cyclophosphamide or 5-fluorouracil: results of first national randomized study. J Urol. 1975;114:909-911.
6. Eisenberger MA. Chemotherapy for prostate carcinoma [review]. NCI Monogr. 1988;(7):151-163.
7. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer. 1993;71:1098-1109.
8. Breul J, Jakse G, Forster G, Lampel A, Rohani A, Hartung R. 5-Fluorouracil versus folinic acid and 5-fluorouracil in advanced, hormone-resistant prostate cancer: a prospective randomized pilot trial. Eur Urol. 1997;32:280-283.
9. Daliani DD, Eisenberg PD, Weems J, Lord R, Fueger R, Logothetis CJ. The results of a phase II randomized trial comparing 5-fluorouracil and 5-fluorouracil plus alpha-interferon: observations on the design of clinical trials for androgen-independent prostate cancer. J Urol. 1995;153:1587-1591.
10. Hansen R, Moynihan T, Beatty P, et al. Continuous systemic 5-fluorouracil infusion in refractory prostatic cancer. Urology. 1991;37:358-361.
11. Kuzel TM, Tallman MS, Shevrin D, et al. A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer. An Illinois Cancer Center Study. Cancer. 1993;72:1965-1968.
12. Berlin JD, Propert KJ, Trump D, et al. 5-Fluorouracil and leucovorin therapy in patients with hormone refractory prostate cancer: an Eastern Cooperative Oncology Group phase II study (E1889). Am J Clin Oncol. 1998;21:171-176.
13. Singh D, Doroshow JH, Leong L, et al. Phase II trial of 5-fluorouracil, high-dose leucovorin calcium, and dipyridamole in advanced prostate cancer. J Cancer Res Clin Oncol. 1992;119:117-120.
14. Shinohara N, Demura T, Matsumura K, et al. 5-fluorouracil and low-dose recombinant interferon-alpha-2a in patients with hormone-refractory adenocarcinoma of the prostate. Prostate. 1998;35:56-62.
15. Unemi N, Harima K, Daidai Y, Fujihara H, Fujii S. [Experimental studies on antineoplastic action of N 1-(2′-tetrahydrofuryl)-5-fluorouracil (FT-207)-effect on experimental tumors]. Jpn J Cancer Clin. 1971;17:731-742.
16. Toide H, Akiyoshi H, Minato Y, Okuda H, Fujii S. Comparative studies on the metabolism of 2-(tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil. Jpn J Cancer Res. 1977;68:553-560.
17. Ikenaka K, Shirasaka T, Kitano S, Fujii S. Effect of uracil on metabolism of 5-fluorouracil in vitro. Jpn J Cancer Res. 1979;70:353-359.
18. Fujii S, Kitano S, Ikenaka K, Shirasaka T. Effect of coadministration of uracil or cytosine on the anti-tumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents. Jpn J Cancer Res. 1979;70:209-214.
19. Ansfield FJ, Kallas GJ, Singson JP. Phase I-II studies of oral tegafur (ftorafur). J Clin Oncol. 1983;1:107-110.
20. Buroker T, Miller A, Baker L, McKenzie M, Samson M, Vaitkevicius VK. Phase II clinical trial of ftorafur in 5-fluorouracil-refractory colorectal cancer. Cancer Treat Rep. 1977;61:1579-1580.
21. Valdivieso M, Bodey GP, Gottlieb JA, Freireich EJ. Clinical evaluation of ftorafur (pyrimidine-deoxyribose n1-2′-furanidyl-5-fluorouracil). Cancer Res. 1976;36:1821-1824.
22. Ota K, Taguchi T, Kimura K. Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol. 1988;22:333-338.
23. Ho DH, Covington W, Brown N, et al. Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity in patients with metastatic cancer. Cancer Chemother Pharmacol. 2000;46:351-356.
24. Okabe H, Toko T, Saito H, et al. Augmentation of the chemotherapeutic effectiveness of UFT, a combination of tegafur [1-(2-tetrahydrofuryl)-5- fluorouracil] with uracil, by oral 1-leucovorin. Anticancer Res. 1997;17:157-164.
25. Pazdur R, Lassere Y, Diaz-Canton E, Ho DH. Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 28-day schedule. Cancer Invest. 1998;16:145-151.
26. Pazdur R, Lassere Y, Rhodes V, et al. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol. 1994;12:2296-2300.
27. Smith R, Wickerham DL, Wieand HS, Colangelo L, Mamounas EP. UFT plus calcium folinate vs 5-FU plus calcium folinate in colon cancer. Oncology (Huntingt). 1999;13:44-47.
28. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997;15:110-115.
29. Wada H, Hitomi S, Teramatsu T. Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. West Japan Study Group for Lung Cancer Surgery. J Clin Oncol. 1996;14:1048-1054.
30. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756-1764.
31. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol. 1999;17:2506-2513.
32. Raghavan D, Cox K, Pearson BS, et al. Oral cyclophosphamide for the management of hormone-refractory prostate cancer. Br J Urol. 1993;72:625-628.
33. Brausi M, Jones WG, Fossa SD, et al. High dose epirubicin is effective in measurable metastatic prostate cancer: a phase II study of the EORTC Genitourinary Group. Eur J Cancer. 1995;31A:1622-1626.
34. Petrioli R, Fiaschi AI, Pozzessere D, et al. Weekly epirubicin in patients with hormone-resistant prostate cancer. Br J Cancer. 2002;87:720-725.
35. Roth BJ, Yeap BY, Wilding G, Kasimis B, McLeod D, Loehrer PJ. Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group. Cancer. 1993;72:2457-2460.
36. Trivedi C, Redman B, Flaherty LE, et al. Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma. Cancer. 2000;89:431-436.
37. Morant R, Bernhard J, Dietrich D, et al. Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial. Br J Cancer. 2004;90:1312-1317.
38. Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med. 2004;350:1713-1721.